Photo by enchaxcreative from unsplash
The majority of patients with urothelial cancer do not respond to immune checkpoint blockade directed at the PD-(L)1 axis. Recently, robust profiling data were used to derive predictive biomarker signatures… Click to show full abstract
The majority of patients with urothelial cancer do not respond to immune checkpoint blockade directed at the PD-(L)1 axis. Recently, robust profiling data were used to derive predictive biomarker signatures for both protumorigenic immunity and adaptive antitumor immunity; combining these has greater predictive power than either alone. Clinically, these results suggest that myeloid cells may be primary drivers of nonresponsiveness in urothelial cancer. See related article by Wang et al., p. 4287
Keywords:
myeloid resistance;
resistance futile;
immunotherapy bladder;
futile biomarkers;
cancer;
biomarkers immunotherapy
Journal Title: Clinical Cancer Research
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Cancer Research
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!